August 23, 2009
Zidovudine was the first drug approved for the treatment of HIV. It is a nucleoside analog reverse transcriptase inhibitor, or nuke. These drugs block the reverse transcriptase enzyme. This enzyme changes HIV's genetic material (RNA) into the form of DNA. This has to occur before HIV's genetic code gets inserted into an infected cell's own genetic codes.
There are no absolute rules about when to start ART. You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking HIV medications. Fact Sheet 404 has more information about guidelines for the use of ART.
If you take zidovudine with other ARV drugs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.
Because zidovudine was the first ARV approved, it has been studied more than any other drug. Most new drugs have been tested by comparing them to zidovudine.
"Early treatment" with zidovudine was tested in people with no symptoms of HIV disease. The study showed no benefit to taking zidovudine. But zidovudine is used as part of combination therapy for people who are exposed to HIV through a workplace accident (needlestick or splash).
Zidovudine greatly reduces transmission of HIV from the mother to her child. It is given to HIV-positive pregnant women from the 4th month of pregnancy until their baby is born, and to the newborn baby for 6 weeks.
Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called "cross-resistance."
Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.
Zidovudine is also available in Combivir and Trizivir. Combivir contains zidovudine and lamivudine. Trizivir contains zidovudine, lamivudine, and abacavir. For more information, see Fact Sheet 417 on Combivir or Fact Sheet 418 on Trizivir.
The most serious side effects of zidovudine are anemia, neutropenia, and myopathy. These side effects are not common.
Anemia is a shortage of red blood cells caused by damage to bone marrow. It is most common in newborn infants taking zidovudine but disappears after they stop taking the drug. If you get anemia, your health care provider might reduce your dose or switch zidovudine for another ARV. If the anemia is severe and you have to keep taking zidovudine, you may need a blood transfusion, or you might take the drug erythropoietin. For more information on anemia, see Fact Sheet 552.
Myopathy is muscle pain and weakness. There is no specific treatment for myopathy.
Neutropenia is an abornormally low number of neutrophils, the most common type of white blood cell. Neutropenia increases the risk of bacterial and fungal infections.
Changes in skin and nail color (darkening of skin and nails) can also occur. This is more common in people with darker skin.
Zidovudine's side effects may be worse if taken with several other drugs.
Methadone may increase blood levels of zidovudine. If you take zidovudine and methadone, watch for zidovudine side effects.